This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
News: Publications

Breaking news - Rare Lipid Disorder Statement published

Monday 7 October 2019  
Share |

New European Atherosclerosis Society Task Force Statement on rare lipid dyslipidaemias

Advances in gene testing offer a ‘precision medicine’ approach to developing new therapies for rare lipid dyslipidaemias. Yet as each of these conditions may only affect about 50 in 100,000 people, diagnosis and treatment remains a challenge. With this in mind, this European Atherosclerosis Society (EAS) Task Force has provided practical clinical guidance specifically for people with either extremely low or extremely high plasma levels of either low-density lipoprotein cholesterol (LDL-C), triglycerides, or high-density lipoprotein cholesterol (HDL-C). This new Task Force Statement has now been published in The Lancet Diabetes & Endocrinology.

Commenting on the need for this guidance, lead author Professor Robert A. Hegele, Robarts Research Institute, Western University, Ontario, Canada, said: ‘The decreasing costs of DNA sequencing has renewed interest in the rare lipid dyslipidaemia field. Yet, the pace of change has overlooked many of the uncertainties that clinicians already have, as they may only see one or two affected people in their entire careers. We provide important practical information to address the questions typically posed by clinicians, to improve the underdiagnosis and undertreatment of these rare conditions.’

To the full press release >>

To the article >>


Membership Software Powered by YourMembership  ::  Legal